ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 2141 • 2019 ACR/ARP Annual Meeting

    Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients

    Kristin D'Silva1, Marcy Bolster 1, Flavia Castelino 2, Amita Sharma 1, Brent Little 1, Sydney Montesi 1 and Hyon K. Choi 1, 1Massachusetts General Hospital, Boston, MA, 2Harvard University, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue diseases (CTD). Approximately one-third of patients with…
  • Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting

    Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?

    Muhsen Al-ani1, Bobby Kwanghoon Han 2 and Gregory c Gardner 3, 1University of Washington, seattle, WA, 2University of Washington, seattle, 3University of Wasshington, seattle

    Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of  clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
  • Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting

    The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation

    Sara Remuzgo-Martínez1, Diana Prieto-Peña 2, Mónica Calderón-Goercke 2, Victor Manuel Mora Cuesta 3, David Iturbe Fernández 1, Sonia M. Fernández Rozas 3, Jose Manuel Cifrian Martínez 3 and Miguel Angel González-Gay 4, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 3Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 4Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
  • Abstract Number: 189 • 2019 ACR/ARP Annual Meeting

    Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

    Soo-Kyung Cho1, Tracy J. Doyle 2, Hemin Lee 3, Yinzhu Jin 3, Angela Y. Tong 3, Adrian J. Santiago Ortiz 3, Jeffrey Sparks 4 and Seoyoung C. Kim 3, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2Brigham and Women's Hospital, Harvard Medical School, Boston, 3Brigham and Women’s Hospital and Harvard Medical School, Boston, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The prevalence of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patient ranges between 5-10%. ILD leads to high morbidity and mortality in patients…
  • Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting

    Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

    Aryeh Fischer1, Oliver Distler 2, Dinesh Khanna 3, Yannick Allanore 4, Anna Maria Hoffmann-Vold 5, Gabriele Valentini 6, Toby Maher 7, Martin Aringer 8, Leslie Meng 9, Margarida Alves 10, Martina Gahlemann 11, Manuel Quaresma 10 and Masataka Kuwana 12, 1University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 4Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 5Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 6Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, 7National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, 8Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 11Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 12Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan

    Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
  • Abstract Number: 2298 • 2019 ACR/ARP Annual Meeting

    Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis

    Raul Castellanos-Moreira1, Sebastian Rodriguez-Garcia 2, Virginia Ruiz-Esquide 3, Fernanda Hernández-González 4, Marcelo Sánchez 5, José Ramírez 6, Mariana Benegas 5, Carmen Lucena-Pozo 4, Carlos Agustí 4, Marc Boada 7, Odette Viñas 8, Estíbaliz Ruiz 8, Sergio Prieto-González 9, Jose Gomez-Puerta 1, Jacobo Sellares 4, Juan Cañete 1, Isabel Haro 10 and Raimon Sanmarti 1, 1Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 2Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, 3Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, 4Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, 5Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, 6Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, 7Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, 8Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, 9Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, 10Unit of Synthesis and Biomedical Applications of Peptides, IQAC CSIC, Barcelona, Barcelona, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of rheumatoid arthritis (RA). It has been associated with the presence of ACPA. Anti-carbamylated…
  • Abstract Number: 369 • 2019 ACR/ARP Annual Meeting

    Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review

    Esteban Rubio1, Alejandro Muñoz 1 and Núria Casamira 2, 1Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, 2Medical Department, Gebro Pharma S.A., Barcelona, Spain

    Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases.  Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
  • Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting

    Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial

    Maureen Mayes1, Kristin Highland 2, Martina Gahlemann 3, Aryeh Fischer 4, Ganesh Raghu 5, Mannaig Girard 6, Margarida Alves 7, Susanne Stowasser 7, Jörg Distler 8, Marco Matucci-Cerinic 9, Elizabeth Volkmann 10, Masataka Kuwana 11 and Oliver Distler 12, 1Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 2Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, 3Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 4University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 5University of Washington, Seattle, USA, Seattle, 6Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 9University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, 10University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 11Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, 12Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

    Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
  • Abstract Number: 2339 • 2019 ACR/ARP Annual Meeting

    Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind

    Sebastian Rodriguez-Garcia1, Raul Castellanos-Moreira 2, Fernanda Hernández-González 3, Albert Perez 4, Joel Francesqui 5, Sandra Cuerpo-Cardeñosa 5, Virginia Ruiz-Esquide 6, Mariana Benegas 7, José Ramírez 8, Carmen Lucena-Pozo 3, Carlos Agustí 3, Marc Boada 9, Estíbaliz Ruiz 4, Odette Viñas 4, Sergio Prieto-González 10, Raimon Sanmarti 11, Gerard Espinosa 12, Mariona Pascal 13, Jose Gomez-Puerta 11, Marcelo Sánchez 7 and Jacobo Sellares 3, 1Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, 2Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, 3Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, 4Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, 5Pneumology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, 6Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, 7Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, 8Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, 9Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, 10Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, 11Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 12Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, 13Immunology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain

    Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is an extra-articular manifestation with a poor prognosis. In clinical practice, to establish such a diagnosis requires…
  • Abstract Number: 370 • 2019 ACR/ARP Annual Meeting

    Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features

    Sogol Amjadi1, Tracy Frech 2, Jessica Chan 3, Mary Beth Scholand 4, Troy Jaskowski 5, Sonia La’ulu 5, Jonathan Genzen 6, Dorota Lebiedz-Odrobina 7 and Ann Tebo 6, 1University of Utah, Department of Internal Medicine, Division of Rheumatology, West Jordan, UT, 2Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, 3University of Utah, Department of Radiology, salt lake city, UT, 4University of Utah, Department of Internal Medicine, Division of Pulmonary Medicine, salt lake city, UT, 5ARUP Institute for Clinical and Experimental Pathology, salt lake city, UT, 6ARUP Institute for Clinical and Experimental Pathology , University of Utah, Department of Pathology, salt lake city, UT, 7University of Utah, Division of Rheumatology, Salt Lake City, UT

    Background/Purpose: Fibrotic lung diseases encompass a wide spectrum of clinical entities including connective tissue disease related interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune…
  • Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use

    Madelon Vonk1, Oliver Distler 2, Daniel Furst 3, Eric Hachulla 4, Sindhu Johnson 5, Shervin Assassi 6, Leslie Meng 7, Manuel Quaresma 8, Margarida Alves 8, Emmanuelle Clerisme-Beaty 8 and Wim Wuyts 9, 1Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3University of California, Los Angeles, CA, 4Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, 5Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, 6Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 7Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 9Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium

    Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…
  • Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting

    Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis

    Takeshi Shoda1, Tohru Takeuchi 2, Takuya Kotani 2, Koji Nagai 2, Kennichiro Hata 2, Shigeki Makino 2 and Shigeki Arawaka 2, 1Yodogawa christian hospital / Osaka medical college, Osaka, Japan, 2Osaka medical college, Osaka, Japan

    Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
  • Abstract Number: 374 • 2019 ACR/ARP Annual Meeting

    The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases

    Eric Matteson1, Clive Kelly 2, Jörg Distler 3, Anna Maria Hoffmann-Vold 4, James Seibold 5, Shikha Mittoo 6, Oliver Distler 7, Rainer-Georg Goeldner 8, Rozsa Schlenker-Herceg 9, Susanne Stowasser 10, Manuel Quaresma 10 and Kevin Flaherty 11, 1Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 4Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 5Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, 6University Health Network, Toronto, Ontario, Canada, Toronto, Canada, 7Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 8Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 11University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI

    Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
  • Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting

    Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial

    Masataka Kuwana1, Kristin Highland 2, Martina Gahlemann 3, Christopher Denton 4, Aryeh Fischer 5, Maureen Mayes 6, Virginia Steen 7, Dinesh Khanna 8, Yannick Allanore 9, Mannaig Girard 10, Margarida Alves 11, Susanne Stowasser 11 and Oliver Distler 12, 1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, 2Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, 3Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 4University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, 5University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 6Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 7Georgetown University, Washington, D.C., USA, Georgetown, 8Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 9Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 10Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, 11Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 12Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

    Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
  • Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting

    Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease

    Scott Matson1, Kevin Deane 2, Christopher Collora 1, Xi Zheng 1, Marie Fester 1, Joyce Lee 1 and M. Kristen Demoruelle 3, 1University of Colorado, Denver, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora

    Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences